期刊
JCI INSIGHT
卷 7, 期 12, 页码 -出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.152466
关键词
-
资金
- NIH [R01HL141086, R01AR070299, R03HD104065]
- Children's Discovery Institute of Washington University
- St. Louis Children's Hospital [PM-LI-2019-829]
- Eunice Kennedy Shriver NICHD of the NIH [3P50HD103525-01S1]
- Washington University Institute of Clinical and Translational Sciences Award from National Center for Advancing Translational Sciences [UL1TR002345]
- [R01AR067715-06]
Nemaline myopathy, as well as other musculoskeletal disorders, is caused by pathogenic variants in the Tropomyosin 2 gene, leading to muscle development and function issues. Through experiments in Drosophila, mice, and zebrafish models, the pathomechanisms of several TPM2 variants were revealed, and it was found that these variants can cause musculoskeletal defects. These assays suggest that our myogenic experiments can predict the clinical severity of TPM2 variants.
Nemaline myopathy (NM) is the most common congenital myopathy, characterized by extreme weakness of the respiratory, limb, and facial muscles. Pathogenic variants in Tropomyosin 2 (TPM2), which encodes a skeletal muscle???specific actin binding protein essential for sarcomere function, cause a spectrum of musculoskeletal disorders that include NM as well as cap myopathy, congenital fiber type disproportion, and distal arthrogryposis (DA). The in vivo pathomechanisms underlying TPM2-related disorders are unknown, so we expressed a series of dominant, pathogenic TPM2 variants in Drosophila embryos and found 4 variants significantly affected muscle development and muscle function. Transient overexpression of the 4 variants also disrupted the morphogenesis of mouse myotubes in vitro and negatively affected zebrafish muscle development in vivo. We used transient overexpression assays in zebrafish to characterize 2 potentially novel TPM2 variants and 1 recurring variant that we identified in patients with DA (V129A, E139K, A155T, respectively) and found these variants caused musculoskeletal defects similar to those of known pathogenic variants. The consistency of musculoskeletal phenotypes in our assays correlated with the severity of clinical phenotypes observed in our patients with DA, suggesting disrupted myogenesis is a potentially novel pathomechanism of TPM2 disorders and that our myogenic assays can predict the clinical severity of TPM2 variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据